Related references
Note: Only part of the references are listed.Farewell to oligoastrocytoma: response to letters
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2015)
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2015)
BRAF V600E Mutations are Frequent in Dysembryoplastic Neuroepithelial Tumors and Subependymal Giant Cell Astrocytomas
Dakeun Lee et al.
JOURNAL OF SURGICAL ONCOLOGY (2015)
Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kasthuri Kannan et al.
Oncotarget (2015)
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2014)
Intratumoral Heterogeneity of Genomic Imbalance in a Case of Epithelioid Glioblastoma with BRAF V600E Mutation
Sumihito Nobusawa et al.
BRAIN PATHOLOGY (2014)
Letter in Response to David N. Louis et al, International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading, Brain Pathology, doi:10.1111/bpa.12171
Johannes Hainfellner
BRAIN PATHOLOGY (2014)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis et al.
BRAIN PATHOLOGY (2014)
Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion
Masaya Nagaishi et al.
BRAIN TUMOR PATHOLOGY (2014)
Desmoplastic non-infantile astrocytic tumor with BRAF V600E mutation
Pinar Karabagli et al.
BRAIN TUMOR PATHOLOGY (2014)
Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases
Dara L. Aisner et al.
CLINICAL NEUROPATHOLOGY (2014)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
Cilengitide in glioblastoma: when did it fail?
Olivier L. Chinot
LANCET ONCOLOGY (2014)
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
Priscilla K. Brastianos et al.
NATURE GENETICS (2014)
BRAF-V600E mutation in pediatric and adult glioblastoma
Sonika Dahiya et al.
NEURO-ONCOLOGY (2014)
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
Benedikt Wiestler et al.
NEURO-ONCOLOGY (2014)
Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity
P. Baumgarten et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
BRAF V600E expression and distribution in desmoplastic infantile astrocytoma/ganglioglioma
C. Koelsche et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2014)
Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors
Jacquelyn J. Roth et al.
CANCER GENETICS (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis
Benedikt Wiestler et al.
ACTA NEUROPATHOLOGICA (2013)
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi et al.
ACTA NEUROPATHOLOGICA (2013)
Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells
Christian Koelsche et al.
ACTA NEUROPATHOLOGICA (2013)
BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma
Sonika Dahiya et al.
ACTA NEUROPATHOLOGICA (2013)
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system
Christian Koelsche et al.
ACTA NEUROPATHOLOGICA (2013)
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Bette Kay Kleinschmidt-DeMasters et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Dysembryoplastic Neuroepithelial Tumors Share with Pleomorphic Xanthoastrocytomas and Gangliogliomas BRAFV600E Mutation and Expression
Celine Chappe et al.
BRAIN PATHOLOGY (2013)
R-2-Hydroxyglutarate as the Key Effector of IDH Mutations Promoting Oncogenesis
Dan Ye et al.
CANCER CELL (2013)
Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation In Vitro
Nico V. Henriquez et al.
CANCER RESEARCH (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
BRAF V600E Mutation Identifies a Subset of Low-Grade Diffusely Infiltrating Gliomas in Adults
Andrew S. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Terri S. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A population-based study of low-grade gliomas and mutated isocitrate dehydrogenase 1 (IDH1)
Rikke H. Dahlrot et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience
J. S. Frenel et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Interlaboratory comparison of IDH mutation detection
Martin J. van den Bent et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Histone 3 Lysine 9 Trimethylation Is Differentially Associated With Isocitrate Dehydrogenase Mutations in Oligodendrogliomas and High-Grade Astrocytomas
Sriram Venneti et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2013)
Molecular neuro-oncology in clinical practice: a new horizon
Michael Weller et al.
LANCET ONCOLOGY (2013)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
David T. W. Jones et al.
NATURE GENETICS (2013)
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas
Haihui Jiang et al.
NEURO-ONCOLOGY (2013)
IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival
Severina Leu et al.
NEURO-ONCOLOGY (2013)
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Wolfgang Wick et al.
NEUROLOGY (2013)
1p/19q testing has no significance in the workup of glioblastomas
K. H. Clark et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Frequency of TERT promoter mutations in human cancers
Joao Vinagre et al.
NATURE COMMUNICATIONS (2013)
Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
David Capper et al.
ACTA NEUROPATHOLOGICA (2012)
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2012)
Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations
Xiao-Yang Liu et al.
ACTA NEUROPATHOLOGICA (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
Pierre Bady et al.
ACTA NEUROPATHOLOGICA (2012)
DNA hypermethylation and 1p Loss silence NHE-1 in oligodendroglioma
Michael D. Blough et al.
ANNALS OF NEUROLOGY (2012)
Frequent BRAF Gain in Low-Grade Diffuse Gliomas with 1p/19q Loss
Young-Ho Kim et al.
BRAIN PATHOLOGY (2012)
Molecular pathogenesis of IDH mutations in gliomas
Koichi Ichimura
BRAIN TUMOR PATHOLOGY (2012)
IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival
Niklas Thon et al.
CANCER (2012)
Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
Dominik Sturm et al.
CANCER CELL (2012)
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma
Qi SongTao et al.
CANCER SCIENCE (2012)
Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
Guido Reifenberger et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas
Rezvan Ahmadi et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers
Stephen Yip et al.
JOURNAL OF PATHOLOGY (2012)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Jeremy Schwartzentruber et al.
NATURE (2012)
A restricted cell population propagates glioblastoma growth after chemotherapy
Jian Chen et al.
NATURE (2012)
Initial treatment patterns over time for anaplastic oligodendroglial tumors
Katherine S. Panageas et al.
NEURO-ONCOLOGY (2012)
Analysis of the BRAFV600E Mutation in Central Nervous System Tumors
Jae Kyung Myung et al.
TRANSLATIONAL ONCOLOGY (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
Incidence Trends in the Anatomic Location of Primary Malignant Brain Tumors in the United States: 1992-2006
Gabriel Zada et al.
WORLD NEUROSURGERY (2012)
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
David Capper et al.
ACTA NEUROPATHOLOGICA (2011)
Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma
Genevieve Schindler et al.
ACTA NEUROPATHOLOGICA (2011)
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations
Andreas von Deimling et al.
BRAIN PATHOLOGY (2011)
IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee
M. Preusser et al.
CLINICAL NEUROPATHOLOGY (2011)
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Jaime Gallego Perez-Larraya et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Andrew B. Lassman et al.
NEURO-ONCOLOGY (2011)
BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications
Dora Dias-Santagata et al.
PLOS ONE (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Altered Telomeres in Tumors with ATRX and DAXX Mutations
Christopher M. Heaphy et al.
SCIENCE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
Regulation of cancer cell metabolism
Rob A. Cairns et al.
NATURE REVIEWS CANCER (2011)
RAF gene fusions are specific to pilocytic astrocytoma in a broad paediatric brain tumour cohort
Andrew R. J. Lawson et al.
ACTA NEUROPATHOLOGICA (2010)
Association of molecular alterations, including BRAF, with biology and outcome in pilocytic astrocytomas
Craig Horbinski et al.
ACTA NEUROPATHOLOGICA (2010)
Molecular Classification of Low-Grade Diffuse Gliomas
Young Ho Kim et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes
David Capper et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Quantitative Characterization of the Interactions among c-myc Transcriptional Regulators FUSE, FBP, and FIR
Hsin-hao Hsiao et al.
BIOCHEMISTRY (2010)
Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors
David Capper et al.
BRAIN PATHOLOGY (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes
Thomas S. Jacques et al.
EMBO JOURNAL (2010)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C. Houillier et al.
NEUROLOGY (2010)
Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres
Peter W. Lewis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome
Takuya Watanabe et al.
ACTA NEUROPATHOLOGICA (2009)
Monoclonal antibody specific for IDH1 R132H mutation
David Capper et al.
ACTA NEUROPATHOLOGICA (2009)
Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma
Andrey Korshunov et al.
ACTA NEUROPATHOLOGICA (2009)
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2009)
IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas
Takuya Watanabe et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
Yukinari Kato et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours
K. Jacob et al.
BRITISH JOURNAL OF CANCER (2009)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Overexpression of the Far Upstream Element Binding Protein 1 in Hepatocellular Carcinoma Is Required for Tumor Growth
Uta Rabenhorst et al.
HEPATOLOGY (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas
Tim Forshew et al.
JOURNAL OF PATHOLOGY (2009)
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Koichi Ichimura et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma
D. T. W. Jones et al.
ONCOGENE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402
Caterina Giannini et al.
BRAIN PATHOLOGY (2008)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity
Monika E. Hegi et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas
Fabio M. Iwamoto et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
K. Ichimura et al.
ONCOGENE (2008)
MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas
Judith Wm Jeuken et al.
LABORATORY INVESTIGATION (2007)
Survey of treatment recommendations for anaplastic oligodendroglioma
Lauren E. Abrey et al.
NEURO-ONCOLOGY (2007)
Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation
Tomasz K. Wojdacz et al.
NUCLEIC ACIDS RESEARCH (2007)
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Robert B. Jenkins et al.
CANCER RESEARCH (2006)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss
Constance A. Griffin et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors
JM McDonald et al.
CANCER (2005)
Chromosome 1p loss:: A favorable prognostic factor in low-grade gliomas
M Kujas et al.
ANNALS OF NEUROLOGY (2005)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Epidemiology and etiology of gliomas
H Ohgaki et al.
ACTA NEUROPATHOLOGICA (2005)
Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas
Y Okamoto et al.
ACTA NEUROPATHOLOGICA (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas
T Watanabe et al.
ACTA NEUROPATHOLOGICA (2002)
The Raf/MEK/ERK pathway:: new concepts of activation
C Peyssonnaux et al.
BIOLOGY OF THE CELL (2001)
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss
Y Ino et al.
JOURNAL OF NEUROSURGERY (2000)
Share Paper
